Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model

Lung Cancer

Volumn 88, Issue 1, 2015, Pages 1-8

  Li, Heyan ^a   Wang, Shuo ^a,b   Takayama, Koichi ^a   Harada, Taishi ^a   Okamoto, Isamu ^a   Iwama, Eiji ^a   Fujii, Akiko ^a   Ota, Keiichi ^a   Hidaka, Noriko ^a   Kawano, Yuko ^a   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor; Erlotinib; Nicotine; Nicotine acetylcholine receptor; Non small cell lung cancer; Resistance

Indexed keywords

ALPHA 1 NICOTINIC RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINE; NICOTINIC RECEPTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHRNA1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; NICOTINIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER CELL LINE; MOUSE; MTS ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; SMOKING; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE, INBRED BALB C; MICE, NUDE; NICOTINE; NICOTINIC AGONISTS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NICOTINIC; SMOKING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924529316     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.01.017     Document Type: Article

References (41)

1. American Cancer Society Cancer facts and figures 2014, ASC, Atlanta, GA.
2. Gautam A., Li Z.R., Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003, 22:2135-2142.
3. Egleton R.D., Brown K.C., Dasgupta P. Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. Pharmacol Ther 2009, 121:205-223.
4. Zeng F., Li Y.C., Chen G., Zhang Y.K., Wang Y.K., Zhou S.Q., et al. Nicotine inhibits cisplatin-induced apoptosis in NCI-H446 cells. Med Oncol (Northwood Lond Engl) 2012, 29:364-373.
5. Parsons A., Daley A., Begh R., Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. Br Med J 2010, 340.
6. Clark G.M., Zborowski D.M., Santabarbara P., Ding K., Whitehead M., Seymour L., et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006, 7:389-394.
7. Clark G., Cagnoni R., Ptaszynski M., Hamilton M., Santababara P., Christy-Bittel J., et al. Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?. Lung Cancer-J IASLC 2005, 49:S368.
8. Cataldo J.K., Dubey S., Prochaska J.J. Smoking cessation: an integral part of lung cancer treatment. Oncology 2010, 78:289-301.
9. Nordquist L.T., Simon G.R., Cantor A., Alberts W.M., Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004, 126:347-351.
10. Improgo M.R., Soll L.G., Tapper A.R., Gardner P.D. Nicotinic acetylcholine receptors mediate lung cancer growth. Front Physiol 2013, 4:251.
11. Davis R., Rizwani W., Banerjee S., Kovacs M., Haura E., Coppola D., et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS ONE 2009, 4:9.
12. Dasgupta P., Kinkade R., Joshi B., DeCook C., Haura E., Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci USA 2006, 103:6332-6337.
13. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol 1997, 15:193-222.
14. Catassi A., Servent D., Paleari L., Cesario A., Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res-Rev Mutat Res 2008, 659:221-231.
15. Hukkanen J., Jacob P., Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005, 57:79-115.
16. Connors S.K., Balusu R., Kundu C.N., Jaiswal A.S., Gairola C.G., Narayan S. C/EBP beta-mediated transcriptional regulation of bcl-xl gene expression in human breast epithelial cells in response to cigarette smoke condensate. Oncogene 2009, 28:921-932.
17. Dasgupta P., Rastogi S., Pillai S., Ordonez-Ercan D., Morris M., Haura E., et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006, 116:2208-2217.
18. Dasgupta P., Rizwani W., Pillai S., Kinkade R., Kovacs M., Rastogi S., et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009, 124:36-45.
19. Schaal C., Chellappan S.P. Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res 2014, 12:14-23.
20. Tsai J.R., Chong I.W., Chen C.C., Lin S.R., Sheu C.C., Hwang J.J. Mitogen-activated protein kinase pathway was significantly activated in human bronchial epithelial cells by nicotine. DNA Cell Biol 2006, 25:312-322.
21. Nishioka T., Kim H.S., Luo L.Y., Huang Y., Guo J.J., Chen C.Y. Sensitization of epithelial growth factor receptors by nicotine exposure to promote breast cancer cell growth. Breast Cancer Res 2011, 13:11.
22. Chen R.J., Ho Y.S., Guo H.R., Wang Y.J. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci 2008, 104:283-293.
23. Carlisle D.L., Liu X., Hopkins T.M., Swick M.C., Dhir R., Siegfried J.M. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther 2007, 20:629-641.
24. Wang S., Takayama K., Tanaka K., Takeshita M., Nakagaki N., Ijichi K., et al. Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by alpha 1 nicotinic acetylcholine receptor-mediated activation in PC9 cells. J Thorac Oncol 2013, 8:719-725.
25. Jensen K., Afroze S., Munshi M.K., Guerrier M., Glaser S.S. Mechanisms for nicotine in the development and progression of gastrointestinal cancers. Transl Gastrointest Cancer 2012, 1:81-87.
26. Smith N.R., Baker D., James N.H., Ratcliffe K., Jenkins M., Ashton S.E., et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010, 16:3548-3561.
27. Wagenknecht L.E., Cutter G.R., Haley N.J., Sidney S., Manolio T.A., Hughes G.H., et al. Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. Am J Public Health 1990, 80:1053-1056.
28. Khalil A.A., Jameson M.J., Broaddus W.C., Lin P.S., Chung T.D. Nicotine enhances proliferation, migration, and radioresistance of human malignant glioma cells through EGFR activation. Brain Tumor Pathol 2013, 30:73-83.
29. Ouchi K.F., Yanagisawa M., Sekiguchi F., Tanaka Y. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 2006, 57:693-702.
30. Hill P., Haley N.J., Wynder E.L. Cigarette smoking: carboxyhemoglobin, plasma nicotine, cotinine and thiocyanate vs self-reported smoking data and cardiovascular disease. J Chronic Dis 1983, 36:439-449.
31. Siu E.C.K., Tyndale R.F. Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. Mol Pharmacol 2007, 71:826-834.
32. Maier C.R., Hollander M.C., Hobbs E.A., Dogan I., Linnoila R.I., Dennis P.A. Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev Res 2011, 4:1743-1751.
33. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
34. Sos M.L., Koker M., Weir B.A., Heynck S., Rabinovsky R., Zander T., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009, 69:3256-3261.
35. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999, 291:739-748.
36. Hamilton M., Wolf J.L., Rusk J., Beard S.E., Clark G.M., Witt K., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006, 12:2166-2171.
37. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007, 190:269-319.
38. Benowitz N.L., Hukkanen J., Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009, 192:29-60.
39. Rogers S.W., Gould T.J., Baker T.B. Mouse models and the genetics of nicotine dependence. Monograph 20: phenotypes and endophenotypes foundations for genetic studies of nicotine use and dependence 2005, 133-186. National Cancer Institute.
40. Zheng Y., Ritzenthaler J.D., Rolman J., Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 2007, 37:681-690.
41. Lam D.C.L., Girard L., Ramirez R., Chan W.S., Suen W.S., Sheridan S., et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007, 67:4638-4647.